Khiron Life Sciences has secured an approval from Invima, Colombia’s health agency, to sell three additional Kuida CBD skincare products.
This approval expands on the seven products presently available at retail and online in Colombia.
Sales of the newly-approved product is expected in fourth quarter of this year.
The first consumer brand of Khiron’s wellness business unit, Kuida, which was launched in Q4 2018, is claimed to bring the benefits of cannabidiol (CBD) to skin and body care products for women.
Kuida is currently available in Colombia through large retailers, wholesalers and online channels.
This brand is available at Cafam, Fedco, Grupo Exito and Farmatodo, besides educational and experiential pop-up stores in major cities.
Khiron CEO and director Alvaro Torres said: “The first-to-market strategy for Kuida® has allowed us to establish a large retail partner network we can now build on with this expanded product line.
“Our educational and experiential programs have helped consumers integrate Kuida CBD products into their daily beauty regimen, and with these newly approved products, we are now positioned to further increase our revenue and market reach in Colombia.”
Khiron Life Sciences has core operations in Latin America and is licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
Besides having the first approved set of CBD cosmetic products on shelf in Colombia, the firm is currently facilitating testing to meet all license requirements for commercial cannabis derived products.
